Skip to main
NGEN

NGEN Stock Forecast & Price Target

NGEN Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

NervGen Pharma is in a strong financial position with the recent completion of a $60M financing round, providing significant support for their lead candidate NVG-291. With promising early clinical results and plans to present data from their trial in the second half of 2026, the company is on track for potential FDA approval and commercialization of NVG-291 in 2029, leading to potential increased operating expenses and potential acquisition. In addition, NervGen's strong intellectual property protection secures a well-protected commercial window for their products, further highlighting their potential for success in the neuroreparative therapeutics sector.

Bears say

NervGen Pharma is a clinical-stage biopharmaceutical company currently developing neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. Despite promising results in their Phase 1b/2a trials and upcoming enrollment for their pivotal Phase 3 study, there are significant risks to achieving their estimated market value and price objective of $18 per share by 2026. These risks include potential delays in starting the pivotal trial, negative results from the Phase 3 program, and slower-than-expected sales uptake for their lead candidate, NVG-291. Additionally, the company has a small cash reserve and may require additional capital to complete pivotal development of NVG-291. With competition from larger firms and the uncertain nature of clinical trials, there is no guarantee of future success.

NGEN has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of NervGen Pharma Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About NervGen Pharma Corp (NGEN) Forecast

Analysts have given NGEN a Buy based on their latest research and market trends.

According to 2 analysts, NGEN has a Buy consensus rating as of Jul 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

NervGen Pharma Corp (NGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.